Profound Medical Corp. (TSE:PRN - Free Report) - Investment analysts at Raymond James lifted their FY2024 earnings per share estimates for shares of Profound Medical in a research report issued on Wednesday, December 11th. Raymond James analyst M. Freeman now expects that the company will earn ($1.79) per share for the year, up from their previous estimate of ($1.82). Raymond James has a "Strong-Buy" rating on the stock. The consensus estimate for Profound Medical's current full-year earnings is ($1.90) per share. Raymond James also issued estimates for Profound Medical's Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($1.24) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at $1.50 EPS and FY2028 earnings at $3.43 EPS.
Profound Medical Stock Down 3.1 %
Shares of PRN stock traded down C$0.33 during trading on Monday, reaching C$10.23. The company's stock had a trading volume of 31,328 shares, compared to its average volume of 7,491. The company has a market capitalization of C$250.43 million, a price-to-earnings ratio of -6.16 and a beta of 0.81. Profound Medical has a 1-year low of C$9.55 and a 1-year high of C$15.75. The company has a debt-to-equity ratio of 16.95, a current ratio of 8.61 and a quick ratio of 14.98. The stock's 50-day moving average price is C$10.81 and its 200 day moving average price is C$11.60.
Insider Transactions at Profound Medical
In other Profound Medical news, Senior Officer Thomas Michael Tamberrino bought 13,333 shares of the business's stock in a transaction dated Tuesday, December 10th. The shares were acquired at an average cost of C$10.65 per share, with a total value of C$141,996.45. Also, Director Arun Menawat Dr. purchased 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average price of C$10.65 per share, with a total value of C$213,000.00. Corporate insiders own 8.62% of the company's stock.
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
See Also
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
